Table 1.
Patient characteristics.
| ALK+ NSCLC patients analyzed in this study (n = 43) | ||
|---|---|---|
| Age, median (39–80) | 57 (10) | |
| Sex, % male | 53% | |
| Smoking status (% never smokers)a | 78% | |
| ECOG PS (%) at baseline | ||
| 0 | 26 | |
| 1 | 14 | |
| 2 | 1 | |
| No data | 2 | |
| Histologyb | ||
| adenocarcinoma | 42/43 | |
| ALK fusion variantc | ||
| EML4-ALK V3 | 13 | |
| EML4-ALK V1/V2 | 22 | |
| Other | 4 | |
| No data | 4 | |
| TP53 status at baseline, mutatedd | 11/39 | |
| ALK TKI, patient number | ||
| Crizotinib | 25 | |
| Ceritinib/alectinib/brigatinib | 36 | |
| Lorlatinib | 4 | |
| Chemotherapy | 7 | |
| Follow-up in months (median, [Q3-Q1]) | 37 (52–27) | |
| Number of samples analyzed per patient (mean [range]) | 8 (4–31) | |
| Percentage of cases with treatment-naive samples | 21% | |
| Number of samples at disease progression per patient, mean | 2.8 | |
| Number of TKI lines covered with liquid biopsy per patient, mean | 1.9 | |
SD standard deviation, EML4-ALK echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) fusion, PS performance status, TKI tyrosine kinase inhibitor.
aData available for 41/43 cases.
bOne patient had an ALK+ large-cell neuroendocrine lung carcinoma responsive to ALK inhibitors.
cData available for 39/43 cases; one case with E18A20, one with E9A20, one with K9A20 (KCL1), and one with K24A20 (KIF5B).
dData available for 39 cases by NGS of tissue biopsies at diagnosis of stage IV disease.